|
|
|
|
Document Preview Lorus Therapeutics Announces Interim Clinical Results of Gti-2040 In Combination Chemotherapy for the Treatment of Renal Cell Cancer |
||||
|
|
||||
|
Click "Add to Cart" button to purchase document. |
||||
|
|
||||
|
Title: |
Lorus Therapeutics Announces Interim Clinical Results of Gti-2040 In Combination Chemotherapy for the Treatment of Renal Cell Cancer |
|||
|
Entities: |
||||
|
Date: |
2004 |
|||
|
Size: |
Preview shows 2KB of 9KB total |
|||
|
Price: |
$39 |
|||
|
ID: |
#279430 |
|||
|
|
||||
|
||||
|
|
||||
|
Start of Preview |
||||
CONTACTS:
{TABLE}
{S} {C} {C}
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
{/TABLE}
LORUS THERAPEUTICS ANNOUNCES INTERIM CLINICAL RESULTS OF GTI-2040
IN COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF RENAL CELL CANCER
- Further clinical development plans to proceed -
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, JANUARY 12, 2004 - Lorus Therapeutics Inc. ("Lorus") announced
today interim results from a recently conducted exploratory Phase II clinical
trial of GTI-2040 in patients with advanced, end-stage renal cell cancer in the
United States. This trial was a single-arm pilot study examining the safety and
efficacy of GTI-2040 used in combination with the anticancer agent capecitabine.
To date, data have been collected on 21 patients evaluable for tumor assessment.
One patient is still receiving treatment after eight months of therapy with
GTI-2040 and capecitabine. Four additional patients will be accrued.
The majority of patients had failed two or more prior therapies before entering
the study, exhibited extensive metastases, and were representative of a
population with very poor prognostic outcome in renal cell cancer. In the
present clinical study, few treatment-related toxicities outside of those
already known to occur with the test drugs were observed. Unaudited data
analysis showed that more than half of the 21 evaluable patients in this study
exhibited disease stabilization, ranging up to eight months. Tumor shrinkages of
index tumors compared to baseline measurements were observed in some patients. A
|
End of Preview |
Home Intelligence Services Subscriptions News About Us